Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (MeritRate)
HIV/AIDS
About this trial
This is an interventional treatment trial for HIV/AIDS focused on measuring HIV, CD4/CD8 ratio, immune recovery, maraviroc, efavirenz
Eligibility Criteria
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Experimental
Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
Efavirenz QD + Zidovudine/Lamivudine BID
Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID
Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily). Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)